![conference banner](/images/conference-banner.jpeg)
Abstract
GABAA receptor channels are ubiquitous in the mammalian central nervous system mediating fast inhibitory neurotransmission by becoming permeant to chloride ions in response to GABA. The emphasis of this review is on the rich chemical diversity of ligands that influence GABAA receptor function. Such diversity provides many avenues for the design and development of new chemical entities acting on GABAA receptors. There is also a significant diversity of GABAA receptor subtypes composed of different protein subunits. The discovery of subtype specific agents is a major challenge in the continuing development of GABAA receptor pharmacology. Leads for the discovery of new chemical entities that influence GABAA receptors come from using recombinant GABAA receptors of known subunit composition as has been elegantly demonstrated by the refining of benzodiazepine actions with a1 subunit preferring agents showing sedative properties but not anxiolytic properties. The most recent advances in the therapeutic use of agents acting on GABAA receptors concern the promotion of sound sleep. Many herbal medicines are used to promote sleep and many of their active ingredients include flavonoids and terpenoids known to modulate GABAA receptor function.
Keywords: inhibitory neurotransmitter, ligand-gated ion channels, second membrane-spanning domain (m), schizophrenia, epilepsies, sleep disorders, anxiolytic, benzodiazepines, spatial memory, ethanol
Current Pharmaceutical Design
Title: GABAA Receptor Channel Pharmacology
Volume: 11 Issue: 15
Author(s): Graham A.R. Johnston
Affiliation:
Keywords: inhibitory neurotransmitter, ligand-gated ion channels, second membrane-spanning domain (m), schizophrenia, epilepsies, sleep disorders, anxiolytic, benzodiazepines, spatial memory, ethanol
Abstract: GABAA receptor channels are ubiquitous in the mammalian central nervous system mediating fast inhibitory neurotransmission by becoming permeant to chloride ions in response to GABA. The emphasis of this review is on the rich chemical diversity of ligands that influence GABAA receptor function. Such diversity provides many avenues for the design and development of new chemical entities acting on GABAA receptors. There is also a significant diversity of GABAA receptor subtypes composed of different protein subunits. The discovery of subtype specific agents is a major challenge in the continuing development of GABAA receptor pharmacology. Leads for the discovery of new chemical entities that influence GABAA receptors come from using recombinant GABAA receptors of known subunit composition as has been elegantly demonstrated by the refining of benzodiazepine actions with a1 subunit preferring agents showing sedative properties but not anxiolytic properties. The most recent advances in the therapeutic use of agents acting on GABAA receptors concern the promotion of sound sleep. Many herbal medicines are used to promote sleep and many of their active ingredients include flavonoids and terpenoids known to modulate GABAA receptor function.
Export Options
About this article
Cite this article as:
Johnston A.R. Graham, GABAA Receptor Channel Pharmacology, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021024
DOI https://dx.doi.org/10.2174/1381612054021024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research Opening New Scenarios for Human MAO Inhibitors
Central Nervous System Agents in Medicinal Chemistry Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets The Role of Monosodium Glutamate (MSG) in Epilepsy and other Neurodegenerative Diseases: Phytochemical-based Therapeutic Approa-ches and Mechanisms
Current Pharmaceutical Biotechnology The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism Neurodevelopmental and Neuropsychiatric Perspectives on Respiratory Control: Understanding Congenital and Developmental Disorders
Current Respiratory Medicine Reviews Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Intraoperative Seizures: Anesthetic and Antiepileptic Drugs
Current Pharmaceutical Design Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Current Psychopharmacology Neurological Disorders in Mice Lacking Glycogenes that are Mainly Expressed in Brain
CNS & Neurological Disorders - Drug Targets Impaired Functional Connectivity of the Thalamus in Alzheimer’ s Disease and Mild Cognitive Impairment: A Resting-State fMRI Study
Current Alzheimer Research Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Voltage-Dependent Sodium Channel Blocker Anticonvulsants: An Approach to the Structure-Activity Relationship
Medicinal Chemistry Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets The Canonical Wnt Signaling Pathway in Autism
CNS & Neurological Disorders - Drug Targets Voltage-Dependent Na+ Channels as Targets of BACE1 - Implications for Neuronal Firing and Beyond
Current Alzheimer Research REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology